<DOC>
	<DOCNO>NCT02666157</DOCNO>
	<brief_summary>1 . The recent development novel oral anticoagulant ( NOACs ) , include direct thrombin inhibitor ( dabigatran ) factor Xa inhibitor ( rivaroxaban , apixaban , edoxaban ) , could potentially overcome many drawback warfarin , might provide safe , even effective convenient alternative approach warfarin non-valvular atrial fibrillation ( NVAF ) , especially Asians . 2 . According result meta-analysis comparing Asians non-Asians , NOACs preferentially indicate Asians term efficacy safety . 3 . There randomize control trial sufficient power directly compare efficacy safety among NOACs NVAF , speak Asians Chinese . 4 . Indirect comparison base observation lot limitation heterogeneous background characteristic , difference study design , diversity time within therapeutic range control group . The finding indirect comparison conclusive hypothesis-generating . 5 . This investigator-initiated prospective randomize open blind end-point clinical trial directly compare efficacy safety among 3 NOACs patient NVAF Taiwan . We hypothesize rivaroxaban apixaban non-inferior dabigatran term efficacy .</brief_summary>
	<brief_title>Comparison Efficacy Safety Among Dabigatran , Rivaroxaban , Apixaban Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description>1. participant a. eligible participant randomly assign dabigatran , rivaroxaban , apixaban allocation ratio 1:1:1 - Patients randomly assign receive dabigatran ( 110 150 mg twice daily ) , rivaroxaban ( 15 20 mg daily ) , apixaban ( 5 mg twice daily ) dosage frequency approve Ministry Health Welfare , Taiwan . Reduced dos ( dabigatran 110 mg twice daily , rivaroxaban 10 15 mg daily , apixaban 2.5 mg twice daily ) allow subset patient one follow criterion : age least 80 year , body weight 60 kg , serum creatinine level ≥1.5 mg per deciliter ( 133 μmol per liter ) creatinine clearance around 30 49 ml per minute ) 2. blood sampling , genotyping , measurement biomarkers a. bood sample ( 13 mL ) peripheral vein study subject baseline 10 mL 3 month later , store enzyme-linked immunosorbent assay well genotyping 3. outcome follow-up a. clinical follow-up perform clinical outcome obtain clinic visit , telephone call direct contact participant subject ' family quarterly treatment 2 time , every 6 month</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Known AF ( paroxysmal persistent/ permanent ) suitable ready NOAC treatment plus least one follow criterion Prior ischemic stroke , transient ischemic accident systemic embolism Left ventricular ejection fraction ≤40 % ( document echocardiography contrast ventriculography ) Symptomatic congestive heart failure ( ≥ New York Heart Association Functional Class 2 ) within 6 month screen Age ≥75 year Age ≥65 &lt; 75 year diabetes mellitus , hypertension coronary artery disease Subjects exclude least one follow situation screen : Known severe ( i.e . hemodynamically significant ) mitral stenosis regardless receive operation Time elapse onset stroke ≤7 day Bleeding tendency Creatinine clearance rate ≤30 mL/min Known active liver disease ( persistent elevation alanine aminotransferase , aspartate transaminase alkaline phosphatase ≥3 × upper normal limit ; advanced liver cirrhosis ≥Pugh B ) Pregnancy Recent document active malignancy radiation therapy ( ≤6 month ) expect survive 3 year Unwilling give inform consent Conditions AF require anticoagulation Anemia ( hemoglobin level &lt; 90 g/L ) thrombocytopenia ( platelet count &lt; 100 × 109/L ) Persistent uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) Active infective endocarditis Patients consider unreliable investigator life expectancy less expected duration trial concomitant disease , condition opinion investigator , would allow safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>stroke</keyword>
	<keyword>systemic embolism</keyword>
	<keyword>bleeding</keyword>
	<keyword>oral anticoagulant</keyword>
</DOC>